Merck, Inc.
๐ต๐ญPhilippines
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00998985
MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
Phase 2
Completed
- Conditions
- Postmenopausal OsteoporosisOsteoporosis
- Interventions
- Drug: Placebo to MK-5442Drug: MK-5442Drug: Alendronate SodiumDrug: Vitamin D3Drug: Calcium carbonateDrug: Placebo to Alendronate
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 526
- Registration Number
- NCT00996801
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Sitagliptin/Metformin FDCDrug: Matching placebo to Sitagliptin/Metformin FDCDrug: Matching placebo to glimepiride
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 292
- Registration Number
- NCT00993187
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
Phase 1
Completed
- Conditions
- Chemotherapy-Induced Nausea and VomitingPostoperative Nausea and Vomiting
- Interventions
- Drug: 100 mg MK-0517 (PS80)Drug: 40 mg MK-0517 (non-PS80)Drug: 100 MK-0517 (PS80) + 2 mg midazolamDrug: 90 mg MK-0517 (PS80)Drug: 150 mg MK-0517 (PS80)Drug: 2 mg MidazolamDrug: 100 mg MK-0517 (non-PS80)Drug: 115 mg MK-0517 (PS80)Drug: 150 mg MK-0517 (Non-PS80)Drug: 40 mg AprepitantDrug: 125 mg AprepitantDrug: Placebo
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 188
- Registration Number
- NCT00990821
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00990808
A Study of V503 Given Concomitantly With Menactraโข and Adacelโข in 11 to 15 Year Olds (V503-005)
Phase 3
Completed
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: V503
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1241
- Registration Number
- NCT00988884
Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)
Phase 3
Completed
- Conditions
- Anesthesia
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00988520
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Infliximab
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 380
- Registration Number
- NCT00988832
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00989079
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
Phase 2
Withdrawn
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00988728
ยฉ Copyright 2025. All Rights Reserved by MedPath